The World Health Organization (WHO) has concluded a meeting on Ebola R&D to look at lessons learned from the outbreak and develop a roadmap for future epidemics.
Dr. Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said the Geneva meeting aimed to “come up with a new framework for R&D for diseases with epidemic potential and other health threats, so that next time we can be better prepared, faster and more effective.”
Kieny said, “If something like Ebola ever happens again, the world needs to be ready with a blueprint for an R&D preparedness plan with clear rules, platforms for information sharing, established processes to expedite development and clinical trials—to activate coordinated action and limit the damage.”
The meeting in Geneva, Switzerland, took place as an independent panel of experts tasked to assess the UN global health agency's response to the Ebola outbreak in West Africa concluded in a report that “at present, WHO does not have the operational capacity or culture to deliver a full emergency public health response” and urged investments by its member states to make it fit for purpose.
“Ebola is not the only epidemic-prone disease for which there are no medicines, vaccines or diagnostics. Nor is this the first time the world has been caught unprepared in the face of an epidemic,” said Kieny. “With more frequent travel, globalized trade and greater interconnectedness between countries, disease outbreaks that once used to be localized and quickly extinguished now have a much greater chance of spreading more widely. Therefore, we as a global community need to be prepared for such a possibility in the future.”
To date, the Ebola outbreak in West Africa has affected more than 26,000 people and left some 11,000 dead.
Dr. Margaret Chan, WHO director-general, said the Ebola R&D effort has mobilized people, institutions and resources in ways never before seen in an “otherwise horrific human calamity” and noted that the world was “likely very close to having a vaccine that can protect against Ebola.”
Kieny said that thanks to “this joining of forces from all corners of the world and different sectors accelerating all actions, we now have commercial diagnostics to detect Ebola, and at least two possibly effective vaccines. These results would normally have taken five to 10 years. All this was done in less than 10 months. Even as Ebola wanes and some of the R&D efforts may not reach the goals aspired, the pioneering work done so far can be leveraged to put in place standards and best practices to improve expedited data and results sharing.”